News | September 19, 2007

Breast Cancer Treatment Hard on the Bones, Study Says

September 20, 2007 - The bones of breast cancer patients tend to age prematurely as a result of chemotherapy and aromatase inhibitor therapy, according to research reported at the American Society for Bone and Mineral Research meeting this week.

The researchers advise that the bone health of these women be evaluated as if this were a much older population of women.

Dr. Pauline M. Camacho and colleagues at Loyola University in Chicago, Illinois, took a look back at the charts of 238 postmenopausal women referred to their institution between 2000-2005 for the management of osteoporosis or osteopenia -- a bone-thinning condition just short of osteoporosis.

Sixty-four women had a history of breast cancer, while 174 "control" women did not. The women with breast cancer had early-stage disease and were in the midst of, or considering, hormonal therapy with aromatase inhibitors.

Roughly three-quarters of the women in both groups had at least one secondary cause of osteoporosis, the researchers found. Vitamin D deficiency was the most common for both groups. The investigators found that 37.5 percent of the breast cancer group and in 51.1 percent of the non-breast cancer group were vitamin D-deficient.

"There is a high prevalence of secondary causes of osteoporosis among breast cancer patients undergoing or considering undergoing adjuvant hormonal therapy with aromatase inhibitors," Camacho told meeting attendees. "This prevalence was similar to the non-breast cancer group despite a difference in age."

"It is prudent" to measure bone mineral content before treatment, Camacho said, "and to screen patients with breast cancer for secondary causes of bone loss."

"These women should be evaluated as if they were much older," she added in an interview with Reuters Health. "It may be wise to keep them on tamoxifen, which is bone-sparing and avoid the aromatase inhibitors, which cause bone loss." Examples of aromatase inhibitors include anastrozole, sold as Arimidex, and exemestane sold as Aromasin.

For more information: www.asbmr.org

Related Content

MR-HIFU, ThermoDox, combination therapy, recurrent childhood tumors, Celsion, Children's National Health System, Phase I clinical study
News | Oncology Related Products | December 19, 2016
December 19, 2016 — Children’s National Health System and Celsion Corp.
News | Clinical Decision Support | October 27, 2016
October 27, 2016 — The National Comprehensive Cancer Network (NCCN) continues to build its library of appropriate use
contrast-enhanced ultrasound, CEUS, liver cancer, hepatocellular carcinoma, study, Advances in Contrast Ultrasound conference, ICUS
News | Ultrasound Imaging | September 12, 2016
September 12, 2016 — Tiny microbubbles are being used to more effectively...
cardio-oncology, echo strain assessment, echoinsight, epsilon

Epsilon's EchoInsight software helps analyze cardiac function by evaluating wall motion strain. 

Feature | Cardio-oncology | May 13, 2016 | Dave Fornell
Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat
Carestream, Clinical Collaboration Platform, Fox Valley Hematology & Oncology
News | Enterprise Imaging | April 20, 2016
Fox Valley Hematology & Oncology (Appleton, Wis.) implemented Carestream’s Vue for Clinical Collaboration Platform...
cancer immunotherapy, development, Axel Hoos, Nature Reviews, imaging
News | Oncology Related Products | March 31, 2016
In a paper published in Nature Reviews last week, Axel Hoos, M.D., Ph.D., laid out the current immunotherapy...
Pyrexar, buy back outside ownership, Person Medical, BSD-2000 Hyperthermia System

BSD-2000 image courtesy of Pyrexar Medical

News | Oncology Related Products | March 15, 2016
Pyrexar announced it has purchased back outside ownership from Person Medical (formerly BSD Medical), concluding a...
BTG, LC Bead LUMI, radiopaque embolic bead, Philips Healthcare, Live Image Guidance, liver cancer
News | Interventional Radiology | February 09, 2016
BTG plc and Royal Philips announced a significant milestone in their collaboration with the treatment of the first...
Overlay Init